229 related articles for article (PubMed ID: 12555297)
41. Is MSI-H of value in predicting the development of metachronous colorectal cancer?
Lawes DA; Pearson T; Sengupta S; Boulos PB
Eur J Cancer; 2006 Mar; 42(4):473-6. PubMed ID: 16427780
[TBL] [Abstract][Full Text] [Related]
42. Surgical treatment of advanced colorectal cancer in the elderly.
Chiappa A; Zbar AP; Bertani E; Biffi R; Luca F; Pace U; Viale G; Pruneri G; Orecchia R; Lazzari R; Biella F; Grassi C; Zampino G; Fazio N; Della Vigna P; Andreoni L; Andreoni B
Chir Ital; 2005; 57(5):589-96. PubMed ID: 16241089
[TBL] [Abstract][Full Text] [Related]
43. Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival.
Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
Anticancer Res; 2006; 26(2B):1425-32. PubMed ID: 16619554
[TBL] [Abstract][Full Text] [Related]
44. An anticancer drug sensitivity test to determine the effectiveness of UFT as postoperative adjuvant chemotherapy for patients with stage III colorectal cancer.
Isogai A; Nagaya M; Matsuoka H; Watanabe T; Tsukikawa S; Kubota S
Surgery; 2007 Nov; 142(5):741-8. PubMed ID: 17981195
[TBL] [Abstract][Full Text] [Related]
45. Colorectal cancer in young patients: characteristics and outcome.
Lee PY; Fletcher WS; Sullivan ES; Vetto JT
Am Surg; 1994 Aug; 60(8):607-12. PubMed ID: 8030817
[TBL] [Abstract][Full Text] [Related]
46. A comparison of the genetic pathways involved in the pathogenesis of three types of colorectal cancer.
Tomlinson I; Ilyas M; Johnson V; Davies A; Clark G; Talbot I; Bodmer W
J Pathol; 1998 Feb; 184(2):148-52. PubMed ID: 9602705
[TBL] [Abstract][Full Text] [Related]
47. The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
Tsamandas AC; Kardamakis D; Ravazoula P; Zolota V; Salakou S; Tepetes K; Kalogeropoulou C; Tsota I; Kourelis T; Makatsoris T; Karavias D; Scopa CD; Bonikos DS; Kalofonos HP; Petsas T
Strahlenther Onkol; 2004 Apr; 180(4):201-8. PubMed ID: 15057430
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of genetic mutations of tumor suppresser genes in colorectal cancer patients.
Kubo H; Miki C; Kusunoki M
Hepatogastroenterology; 2004; 51(55):114-7. PubMed ID: 15011843
[TBL] [Abstract][Full Text] [Related]
49. Microsatellite instability and MBD4 mutation in unselected colorectal cancer.
Evertson S; Wallin A; Arbman G; Rütten S; Emterling A; Zhang H; Sun XF
Anticancer Res; 2003; 23(4):3569-74. PubMed ID: 12926109
[TBL] [Abstract][Full Text] [Related]
50. The epidemiology of colorectal cancer: what can we learn from the New Zealand Cancer Registry?
Keating J; Pater P; Lolohea S; Wickremesekera K
N Z Med J; 2003 May; 116(1174):U437. PubMed ID: 12766783
[TBL] [Abstract][Full Text] [Related]
51. Adenocarcinoma of the colon and rectum in patients less than 40 years of age.
MacGillivray DC; Swartz SE; Robinson AM; Cruess DF; Smith LE
Surg Gynecol Obstet; 1991 Jan; 172(1):1-7. PubMed ID: 1985333
[TBL] [Abstract][Full Text] [Related]
52. Impact of socioeconomic deprivation on outcome after surgery for colorectal cancer.
Hole DJ; McArdle CS
Br J Surg; 2002 May; 89(5):586-90. PubMed ID: 11972548
[TBL] [Abstract][Full Text] [Related]
53. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China.
Rashid A; Ueki T; Gao YT; Houlihan PS; Wallace C; Wang BS; Shen MC; Deng J; Hsing AW
Clin Cancer Res; 2002 Oct; 8(10):3156-63. PubMed ID: 12374683
[TBL] [Abstract][Full Text] [Related]
54. Aberration of p53 and DCC in gastric and colorectal cancer.
Kataoka M; Okabayashi T; Johira H; Nakatani S; Nakashima A; Takeda A; Nishizaki M; Orita K; Tanaka N
Oncol Rep; 2000; 7(1):99-103. PubMed ID: 10601600
[TBL] [Abstract][Full Text] [Related]
55. [Genes of micrometastasis in bone marrow of patients with colorectal cancer].
Li S; Luo C; Yu B; Yuan S; Liang Z
Zhonghua Wai Ke Za Zhi; 2000 Mar; 38(3):196-7. PubMed ID: 11832027
[TBL] [Abstract][Full Text] [Related]
56. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.
Ribic CM; Sargent DJ; Moore MJ; Thibodeau SN; French AJ; Goldberg RM; Hamilton SR; Laurent-Puig P; Gryfe R; Shepherd LE; Tu D; Redston M; Gallinger S
N Engl J Med; 2003 Jul; 349(3):247-57. PubMed ID: 12867608
[TBL] [Abstract][Full Text] [Related]
57. Microsatellite instability in colon cancer.
Allegra CJ; Kim G; Kirsch IR
N Engl J Med; 2003 Oct; 349(18):1774-6; author reply 1774-6. PubMed ID: 14585950
[No Abstract] [Full Text] [Related]
58. [Study of microsatellite instability of colotectal cancer and its clinical significance].
Xiong B; Zheng S; Cai X
Zhonghua Zhong Liu Za Zhi; 1999 May; 21(3):199-201. PubMed ID: 11776835
[TBL] [Abstract][Full Text] [Related]
59. Metachronous colorectal cancers.
Fajobi O; Yiu CY; Sen-Gupta SB; Boulos PB
Br J Surg; 1998 Jul; 85(7):897-901. PubMed ID: 9692559
[TBL] [Abstract][Full Text] [Related]
60. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer.
Ward R; Meagher A; Tomlinson I; O'Connor T; Norrie M; Wu R; Hawkins N
Gut; 2001 Jun; 48(6):821-9. PubMed ID: 11358903
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
